Search Answers
Search Crossword Answers
Biopharmaceutical giant in the Fortune 200 Crossword Clue
Here is the answer for the crossword clue Biopharmaceutical giant in the Fortune 200 last seen in New York Times puzzle. We have found 40 possible answers for this clue in our database. Among them, one solution stands out with a 98% match which has a length of 5 letters. We think the likely answer to this clue is AMGEN.
Crossword Answer For Biopharmaceutical giant in the Fortune 200:
You can click on thetiles to reveal letter by letter before uncovering the full solution.
40 Potential Answers:
| Rank | Answer | Length | Source | Date |
|---|---|---|---|---|
| 98% | AMGEN Biopharmaceutical giant in the Fortune 200 | (5) | New York Times | Sep 1, 2023 |
| 6% | FAME ___ and fortune | (4) | ||
| 6% | LUCK Good fortune | (4) | USA Today | Aug 25, 2025 |
| 6% | LOT Fortune | (3) | Thomas Joseph | Aug 14, 2025 |
| 5% | TITAN Giant; moon of Saturn | (5) | The Telegraph Plusword | Sep 13, 2025 |
| 5% | OTIS Vertical transportation giant | (4) | Newsday | Sep 11, 2025 |
| 5% | NOKIA Finnish tech giant | (5) | LA Times Mini | Sep 10, 2025 |
| 5% | TSUNAMI Giant wave | (7) | Wall Street Journal | Sep 8, 2025 |
| 5% | AVIARY Giant birdcage | (6) | Puzzler Backwords | Sep 6, 2025 |
| 5% | EBAY Online auction giant | (4) |
Last appeared together with the following clues in New York Times puzzle
Fresh Clues From Recent Puzzles
Your Crossword Clues FAQ Guide
We found 40 solutions for Biopharmaceutical giant in the Fortune 200. The top solutions are determined by popularity, ratings and frequency of searches. The most likely answer for the clue is AMGEN.
With crossword-solver.io you will find 40 solutions. We use historic puzzles to find the best matches for your question. We add many new clues on a daily basis.
With our crossword solver search engine you have access to over 7 million clues. You can narrow down the possible answers by specifying the number of letters it contains. We found more than 40 answers for Biopharmaceutical giant in the Fortune 200.